Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 117

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 117
---
15(d) of the Exchange Act after the date of this proxy statement and before the date of the MIRA Annual Meeting (excluding any current reports on Form 8-K to the extent disclosure is furnished and not filed). Those documents are considered to be a part of this proxy statement, effective as of the date they are filed. In the event of conflicting information in these documents, the information in the latest filed document should be considered correct.

| 67 |

MIRA has supplied all information contained in this proxy statement relating to MIRA, and SKNY has supplied all information contained in this proxy statement relating to SKNY.

If you would like to request documents from MIRA, please send a request in writing or by telephone to either MIRA or SKNY at the following addresses:

<div align='center'>MIRA Pharmaceuticals, Inc.

1200 Brickell Avenue

Suite 1950 #1183

Miami, FL 33131

Telephone: (786) 423-9792

SKNY Pharmaceuticals, Inc.

3014 West Palmira Ave., Suite 302 Tampa,

FL 33629.

Telephone: (504) 931-642</div>

By Order of the Board of Directors,

|        | /s/                                                      
 Erez Aminov                                              |
| Name:  | Erez                                                     
 Aminov                                                   |
| Title: | Chief                                                    
 Executive Officer and Chairman of the Board of Directors |

| 68 |

Annex A

<div align='center'>AGREEMENT AND PLAN OF MERGER

BY AND AMONG

MIRA Pharmaceutics, INC.,

MIRAPHARM ACQUISITION, INC.

and
SKNY Pharmaceuticals, Inc.

DATED AS OF JUNE16, 2025</div>

This document is intended solely to facilitate discussions among the parties identified herein. It is not intended to create, and shall not be deemed to create, a legally binding or enforceable offer or agreement of any type or nature prior to the duly authorized and approved execution of this document by all such parties and the delivery of an executed copy hereof by all such parties to all other parties.

<div align='center'>AGREEMENT AND PLAN OF MERGER</div>

THIS AGREEMENT AND PLAN OF MERGER (this “ Agreement”), is dated as of June 16, 2025 (the “ Signing Date”), and made by and among MIRA Pharmaceuticals, Inc., a Florida corporation (the “ Company”), MIRAPHARM Acquisition, Inc., a Delaware corporation and a wholly